## News Release

## **FOR IMMEDIATE RELEASE** March 5, 2020 CONTACT: Suzanna Cisneros, <u>suzanna.cisneros@ttuhsc.edu</u>

(806) 743-7605

## **CPRIT Awards Research Grant to**eynoldsFunds to Aid Childhood, Adolescent Cancer Study

The Cancer Prevention and Research Institute of Texas (CPRIT) in February announced a \$1,196,214 grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center (TTUHSC).

The gtapy, õGD2 Ezr teuuiqp apd Reur qpue vq Cheo qio o wpqvhetar { ip Newtqbrauvqo a,ö y imr tqxide fwpdipg fqt Re{pqrduøqpgqipg ipxeuvigaviqpu ipvq vhe y a{ capcet cemu eucar e from therapy with antibodies that bind to GD2, for which preliminary data suggest the mechanism is loss of GD2 from the cancer cells. Dinutuximab, an antibody binding to GD2, can enhance chemoimmunotherapy both in patients and in preclinical models.

Neuroblastoma is the most common cancer outside of the brain in infants and young children and is challenging to treat, especially in patients that relapse after initial therapy. GD2 is a complex molecule highly expressed on neuroblastoma cells and is a target for successfully treating tumors.

 $\tilde{o}$ Chindtep y ish capcet, bqsh ip Tezau apd be{qpd ate fqtwpase that CPRIT has made fundipg chindhqqd capcet a r tiqtist,  $\tilde{o}$  Re{pqndu uaid.  $\tilde{o}$ This recent grant from CPRIT will enable us to understand how tumor cells escape therapy with an antibody that is effective

